NO20073426L - MTKI kinazolinderivater - Google Patents

MTKI kinazolinderivater

Info

Publication number
NO20073426L
NO20073426L NO20073426A NO20073426A NO20073426L NO 20073426 L NO20073426 L NO 20073426L NO 20073426 A NO20073426 A NO 20073426A NO 20073426 A NO20073426 A NO 20073426A NO 20073426 L NO20073426 L NO 20073426L
Authority
NO
Norway
Prior art keywords
alkyl
2alkyl
4alkyloxy
hydrogen
5alkyl
Prior art date
Application number
NO20073426A
Other languages
English (en)
Other versions
NO339891B1 (no
Inventor
Eddy Jean Edgard Freyne
Werner Constant Joha Embrechts
Marc Willems
Peter Ten Holte
Alexandra Papanikos
Pierre Henri Storck
Virginie Sophie Poncelet
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/EP2005/056609 external-priority patent/WO2006061417A2/en
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Publication of NO20073426L publication Critical patent/NO20073426L/no
Publication of NO339891B1 publication Critical patent/NO339891B1/no

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D498/00Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/06Peri-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/529Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim forming part of bridged ring systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D498/00Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/08Bridged systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Mechanical Treatment Of Semiconductor (AREA)

Abstract

Foreliggende oppfinnelse vedrører forbindelsene med formel (I) N-oksidformene, de farmasøytisk akseptable addisjonssalter og de stereokjemisk isomere former derav, hvori Z representerer NH; Y representerer -C3-9alkyl-,-C1-5alkyl-NR13-C1-5alkyl-, -C1-5alkyl-NR14-CO-C1-5alkyl-, -C1-2alkyl-NR21-H2-CO-NH-C1-3alkyl- eller -C1-2alkyl-NR23-CO-CR16R17-NH-; X1 representerer O eller -O-C1-2alkyl-; X2 representerer en direktebinding, C1-2alkyl, -CO-C1-2alkyl eller NR12-C1-2alkyl; R1 representerer hydrogen eller halo; R2 representerer halo, acetylen eller Het1 R3 representerer hydrogen eller cyano; R4 representerer Ar4-C1-4alkyloksy-, C1-4alkyloksy- eller C1-4alkyloksy substituert med én eller hvor mulig to eller flere substituenter valgt fra Het2, NR7R8, hydroksy og C1-4alkyloksy-C1-4alkyloksy-; R7 representerer hydrogen eller C1-4alkyl; R8 representerer C1-4alkyl substituert med NR25R26 eller C1-4alkylsulfonyl; R12 representerer hydrogen eller C1-4alkyl-; R13 representerer Ar6-sulfonyl eller C1-6alkyloksykarbonyl eventuelt substituert med fenyl; R16 og R17 representerer hydrogen, C1-4alkyl eller R16 og R17 tatt sammen med karbonatomet til hvilket de er bundet danner et C3-6cykloalkyl; R23 representerer C1-4alkyl og R23 representerer hydrogen når R16 og R17 tatt sammen med karbonatomet til hvilket de er bundet danner et C3-6cykloalkyl; R25, R26, R27 og R28 representerer hver uavhengig hydrogen eller C1-4alkylkarbonyl; Het1 representerer 2-bora-1,3-dioksolanyl; Het2 representerer piperidinyl, piperazinyl, morfolinyl, tiomorfolinyl eller 1,1-dioksotiomorfolinyl hvori nevnte Het2 eventuelt er substituert med C1-4alkyloksykarbonyl eller NR27R28-C1-4alkyl; Ar4 og Ar5 representerer fenyl; Ar6 representerer fenyl eventuelt substituert med nitro. ?? ?? ?? ?? 1
NO20073426A 2004-12-08 2007-07-05 MTKI kinazolinderivater NO339891B1 (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US63422804P 2004-12-08 2004-12-08
EP04106383 2004-12-08
PCT/EP2005/056609 WO2006061417A2 (en) 2004-12-08 2005-12-08 Macrocyclic quinazole derivatives and their use as mtki

Publications (2)

Publication Number Publication Date
NO20073426L true NO20073426L (no) 2007-07-05
NO339891B1 NO339891B1 (no) 2017-02-13

Family

ID=36228769

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20073426A NO339891B1 (no) 2004-12-08 2007-07-05 MTKI kinazolinderivater

Country Status (4)

Country Link
US (2) US9688691B2 (no)
IL (1) IL183705A (no)
NI (1) NI200700147A (no)
NO (1) NO339891B1 (no)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022182845A1 (en) * 2021-02-25 2022-09-01 Blossomhill Therapeutics, Inc. Macrocycles and their use

Family Cites Families (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE558251A (no) 1956-06-11
DE2423536A1 (de) 1974-05-15 1975-11-27 Bayer Ag 3-amino-phenylessigsaeure-derivate, verfahren zu ihrer herstellung sowie ihre verwendung als herbizide
NZ181256A (en) 1975-07-21 1978-04-28 Janssen Pharmaceutica Nv 1-(w-benzazol-11-ylalkyl)-piperidine derivatives and pharmaceutical compositions containing certain of these derivatives
US4110333A (en) 1976-05-17 1978-08-29 Janssen Pharmaceutica N.V. 1,3-Dihydro-1-[3-(1-piperidinyl)propyl]-2H-benzimidazol-2-ones and related compounds
US4442278A (en) 1981-12-03 1984-04-10 Hughes Aircraft Company Ethynyl-substituted s-triazine derivatives, polymers thereof and process for making the same
US5721237A (en) 1991-05-10 1998-02-24 Rhone-Poulenc Rorer Pharmaceuticals Inc. Protein tyrosine kinase aryl and heteroaryl quinazoline compounds having selective inhibition of HER-2 autophosphorylation properties
IL112248A0 (en) 1994-01-25 1995-03-30 Warner Lambert Co Tricyclic heteroaromatic compounds and pharmaceutical compositions containing them
US5679683A (en) 1994-01-25 1997-10-21 Warner-Lambert Company Tricyclic compounds capable of inhibiting tyrosine kinases of the epidermal growth factor receptor family
IL112249A (en) 1994-01-25 2001-11-25 Warner Lambert Co Pharmaceutical compositions containing di and tricyclic pyrimidine derivatives for inhibiting tyrosine kinases of the epidermal growth factor receptor family and some new such compounds
TW414798B (en) 1994-09-07 2000-12-11 Thomae Gmbh Dr K Pyrimido (5,4-d) pyrimidines, medicaments comprising these compounds, their use and processes for their preparation
GB9510757D0 (en) 1994-09-19 1995-07-19 Wellcome Found Therapeuticaly active compounds
DE69502028T2 (de) 1994-10-31 1998-12-10 Dsm N.V., Heerlen Katalytische zusammensetzung und verfahren zur olefinpolymerisation
GB9508538D0 (en) 1995-04-27 1995-06-14 Zeneca Ltd Quinazoline derivatives
DE19608588A1 (de) 1996-03-06 1997-09-11 Thomae Gmbh Dr K Pyrimido [5,4-d]pyrimidine, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung
HU228446B1 (en) 1996-04-12 2013-03-28 Warner Lambert Co Kinazoline derivatives as irreversible inhibitors of protein-kinase, pharmaceutical compositions containing these compounds and use thereof
GB9718972D0 (en) 1996-09-25 1997-11-12 Zeneca Ltd Chemical compounds
UA73073C2 (uk) 1997-04-03 2005-06-15 Уайт Холдінгз Корпорейшн Заміщені 3-ціанохіноліни, спосіб їх одержання та фармацевтична композиція
US6002008A (en) 1997-04-03 1999-12-14 American Cyanamid Company Substituted 3-cyano quinolines
EE200000386A (et) 1997-12-24 2001-12-17 Vertex Pharmaceuticals Incorporated Aspartüülproteaasi inhibiitorite eelravimid
WO1999033792A2 (en) 1997-12-24 1999-07-08 Vertex Pharmaceuticals Incorporated Prodrugs os aspartyl protease inhibitors
AU2012199A (en) 1997-12-24 1999-07-19 Vertex Pharmaceuticals Incorporated Prodrugs of aspartyl protease inhibitors
US6436989B1 (en) 1997-12-24 2002-08-20 Vertex Pharmaceuticals, Incorporated Prodrugs of aspartyl protease inhibitors
US6288082B1 (en) 1998-09-29 2001-09-11 American Cyanamid Company Substituted 3-cyanoquinolines
BR9914167B1 (pt) 1998-09-29 2011-03-09 compostos e composições farmacêuticas compreendendo 3-ciano quinolinas substituìdas.
ATE232205T1 (de) 1998-10-01 2003-02-15 Astrazeneca Ab Chinolin- und chinazolin derivate und ihre verwendung als inhibitoren von krankheiten, bei denen cytokine beteiligt wird
GB9904995D0 (en) 1999-03-04 1999-04-28 Glaxo Group Ltd Substituted aza-oxindole derivatives
CA2381821A1 (en) 1999-08-27 2001-03-08 Boehringer Ingelheim Pharma Kg Substituted indolinones, their manufacture and their use as medicaments
WO2001025220A1 (en) 1999-10-07 2001-04-12 Amgen Inc. Triazine kinase inhibitors
AU2001288374A1 (en) 2000-09-01 2002-03-22 Glaxo Group Limited Substituted oxindole derivatives as tyrosine kinase inhibitors
US6864255B2 (en) 2001-04-11 2005-03-08 Amgen Inc. Substituted triazinyl amide derivatives and methods of use
BR0210391A (pt) 2001-06-12 2004-06-15 Elan Pharm Inc Composto, métodos de tratar um paciente que tenha ou de prevenir um paciente de contrair uma doença ou condição e de preparar um composto, e, uso de um composto
US7501516B2 (en) 2001-07-16 2009-03-10 Astrazeneca Ab Quinoline derivatives and their use as tyrosine kinase inhibitors
NZ535232A (en) 2002-02-28 2007-05-31 Univ Temple Amino-substituted (E)-2,6-dialkoxystyryl 4-substituted benzylsulfones for treating proliferative disorders
CA2476008C (en) 2002-03-30 2011-12-13 Boehringer Ingelheim Pharma Gmbh & Co. Kg Bicyclic heterocyclic compounds, pharmaceutical compositions containing these compounds, their use and process for preparing them
US6924285B2 (en) 2002-03-30 2005-08-02 Boehringer Ingelheim Pharma Gmbh & Co. Bicyclic heterocyclic compounds, pharmaceutical compositions containing these compounds, their use and process for preparing them
WO2004004732A1 (en) 2002-07-09 2004-01-15 Astrazeneca Ab Quinazoline derivatives for use in the treatment of cancer
EP1546121B1 (en) 2002-07-18 2012-08-29 Janssen Pharmaceutica NV Substituted triazine kinase inhibitors
MXPA05001544A (es) 2002-08-08 2005-04-19 Smithkline Beecham Corp Compuestos de tiofeno.
DE10239042A1 (de) 2002-08-21 2004-03-04 Schering Ag Makrozyclische Pyrimidine, deren Herstellung und Verwendung als Arzneimittel
US7148249B2 (en) 2002-09-12 2006-12-12 Boehringer Ingelheim Pharma Gmbh & Co. Kg Indolinones substituted by heterocycles, the preparation thereof and their use as medicaments
AU2003286711A1 (en) 2002-10-25 2004-05-13 Vertex Pharmaceuticals Incorporated Indazolinone compositions useful as kinase inhibitors
AU2003284399A1 (en) 2002-11-14 2004-06-03 Kyowa Hakko Kogyo Co., Ltd. Plk inhibitors
SE0300480D0 (sv) 2003-02-21 2003-02-21 Astrazeneca Ab Novel compounds
WO2004078682A2 (en) 2003-03-05 2004-09-16 Irm Llc Cyclic compounds and compositions as protein kinase inhibitors
PA8603801A1 (es) 2003-05-27 2004-12-16 Janssen Pharmaceutica Nv Derivados de la quinazolina
UA83881C2 (en) 2003-12-18 2008-08-26 Янссен Фармацевтика Н.В. Pyrido- and pyrimidopyrimidine derivatives as anti-proliferative agents
ATE446750T1 (de) 2003-12-18 2009-11-15 Janssen Pharmaceutica Nv 3-cyano-chinolin-derivate mit antiproliferativer wirkung
JO3088B1 (ar) 2004-12-08 2017-03-15 Janssen Pharmaceutica Nv مشتقات كوينازولين كبيرة الحلقات و استعمالها بصفتها موانع كينيز متعددة الاهداف
MY169441A (en) 2004-12-08 2019-04-11 Janssen Pharmaceutica Nv 2,4, (4,6) pyrimidine derivatives
WO2007003525A2 (en) 2005-06-30 2007-01-11 Janssen Pharmaceutica N.V. Cyclic anilino-pyridinotriazines as gsk-3 inhibitors
JP2007135441A (ja) 2005-11-16 2007-06-07 Kenichi Mikiya 新規タンパク質及びそれをコードする遺伝子
NZ568325A (en) 2005-11-16 2011-05-27 S Bio Pte Ltd Macrocyclic oxygen linked pyrimidine derivatives
CA2654583C (en) 2006-07-13 2015-11-24 Janssen Pharmaceutica N.V. Mtki quinazoline derivatives
CA2664148A1 (en) 2006-10-27 2008-05-02 Janssen Pharmaceutica Nv Vegfr3 inhibitors
CA2687909C (en) 2007-06-21 2015-09-15 Janssen Pharmaceutica Nv Indolin-2-ones and aza-indolin-2-ones
ES2562218T3 (es) 2007-07-27 2016-03-03 Janssen Pharmaceutica, N.V. Pirrolopirimidinas útiles para el tratamiento de enfermedades proliferativas
EP2283024B1 (en) 2008-03-10 2013-05-15 Janssen Pharmaceutica, N.V. 4-aryl-2-anilino-pyrimidines as plk kinase inhibitors
WO2011150982A1 (en) * 2010-06-02 2011-12-08 Telefonaktiebolaget L M Ericsson (Publ) Configuring a path in an optical communications network

Also Published As

Publication number Publication date
NO339891B1 (no) 2017-02-13
US10208062B2 (en) 2019-02-19
IL183705A (en) 2012-02-29
US20140256714A1 (en) 2014-09-11
US9688691B2 (en) 2017-06-27
US20170320894A1 (en) 2017-11-09
HK1111416A1 (en) 2008-08-08
NI200700147A (es) 2019-05-10
IL183705A0 (en) 2007-09-20

Similar Documents

Publication Publication Date Title
TW200635933A (en) MTKI quinazoline derivatives
NO20065615L (no) Adamantyl-pyrrolidin-2-onderivater som 11-beta-hydroksysteroiddehydrogenaseinhibitorer
IL188453A0 (en) Cyclic anilino-pyridinotriazines
NO20065619L (no) Pyrrolidin-2-on- og piperidin-2-onderivat som 11-beta-hydroksysteroid-dehydrogenaseinhibitorer
TN2012000033A1 (en) Mixtures of mesoionic pesticides
NO20063323L (no) Pyrido- og pyrimidopyrimidinderivater
NO20063452L (no) Benzamid-derivater og deres anvendelse som glukokinaseaktiversingsmidler
NO20064008L (no) Forbindelser
CL2020002423A1 (es) Nuevos compuestos heterocíclicos
NO20056196L (no) Makrocykliske kinazolinderivater som antiproliferative midler
NO20071697L (no) N-2 Adamantanyl-2-fenoksy-acetamidderivater som 11-beta-hydroksysteroid-dehydrogenaseinhibitorer
WO2003057688A3 (en) Oxo or oxy-pyridine compounds as 5-ht4 receptor modulators
NO20092770L (no) Nye aminopyrimidinderivater som PLK1-inhibitorer
NO20052469L (no) Inhibitorer av II-beta-hydroksysteroid-dehydrogenase type 1 og type 2.
PH12012500487A1 (en) Herbicidal pyrimidone derivatives
TW200738667A (en) Preparation method for dioxan-2-ylalkylcarbamate derivatives and intermediate thereof
PE20070041A1 (es) Amidas de acido pirazolcarboxilico
EA200970121A1 (ru) Производные хиназолина в качестве mtki
NO20073426L (no) MTKI kinazolinderivater
DE602005007064D1 (de) Chromanderivate und ihre verwendung als liganden des 5-ht-rezeptors
TW200738697A (en) Benzimidazole derivatives as 5-HT6,5-HT24
EA200602045A1 (ru) 2-замещённые пиримидины
DE602006014997D1 (de) Diaryltriazolmethylamin-derivate sowie ihre herstellung und therapeutische verwendung
TNSN08521A1 (en) Phenylpentadienoyl derivatives and their use as par 1 antagonists
CL2021000486A1 (es) Derivados de heteroarilo bicíclicos